Mitchell Silberberg & Knupp advised Perfect Moment Ltd. on the offering, and Sichenzia Ross Ference Carmel represented the joint book-running managers. Perfect Moment Ltd. (“Perfect Moment”)...
Perfect Moment’s $8 Million Initial Public Offering
SciSparc Ltd.’s $1.3 Million Ordinary Shares Offering
Sichenzia Ross Ference LLP represented Aegis Capital Corp. in the offering. SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”) announced the closing of a firm commitment underwritten public offering with...
The NFT Gaming Company’s $7 Million Initial Public Offering
Sheppard, Mullin, Richter & Hampton advised the NFT Gaming Company, while Sichenzia Ross Ference LLP represented Laidlaw & Company (UK) Ltd. in the offering. The NFT...
BiondVax Pharmaceuticals’ $8 Million Public Offering
Sichenzia Ross Ference represented Aegis Capital Corp. as sole book running manager in the offering. BiondVax Pharmaceuticals executed the $8 Million underwritten public offering. The offering consisted...
Silo Pharma’s $5.75 Million Public Offering and Nasdaq Uplisting
Sichenzia Ross Ference represented Laidlaw & Company (UK) Ltd. în the transaction while Sheppard Mullin advised Silo Pharma. Silo Pharma, Inc. (Nasdaq: SILO) announced the $5.75 million...
Amesite’s $2.3 Million Direct Offering and Private Placement
Sichenzia Ross Ference LLP represented Laidlaw & Company on the deal while Sheppard Mullin advised Amesite. Amesite Inc announced a registered direct offering of 4,181,821 shares of...
Kaspien Holdings’ $8 Million Direct Offering and Private Placement
Sichenzia Ross Ference represented Aegis Capital Corp., acting as the exclusive placement agent, in the transaction. Kaspien Holdings Inc. (NASDAQ: KSPN), an e-commerce marketplace growth platform,...
SciSparc’s $10 Million Private Placement Offering
Sichenzia Ross Ference represented Aegis Capital Corp. as exclusive placement agent in the offering. SciSparc Ltd. executed its $10,000,000 private placement offering, which consisted of 3,546,100 units at...
Relmada Therapeutics’ $100 Million At-The-Market Offering
Sichenzia Ross Ference represented Relmada Therapeutics in the transaction. Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, executed a $100 million At-The-Market offering facility (“ATM”)....
Relmada Therapeutics’ $172.5 Million Shares Offering
Sichenzia Ross Ference represented Relmada Therapeutics in the offering. Relmada Therapeutics executed its offering which included the full exercise of the overallotment, consisted of 10,147,059 shares of common...
Inmune Bio’s $40.0 Million Shares Offering
Sichenzia Ross Ference represented Inmune Bio in the transaction. Inmune Bio, Inc. executed its registered direct offering of common stock at a purchase price of $22.00 per share...
Alset EHome International’s $32.0 Million Common Stock Offering
Sichenzia Ross Ference LLP represented Alset EHome International Inc. in the transaction. Alset EHome International Inc. (NASDAQ: AEI) executed a public offering, which consisted of 4,700,637 Units (the...